News from CROI 2014

The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) took place in Boston, USA, in early March 2014.

Our writers reported on key research presented at the conference, publishing news and sending out CROI news summary bulletins by email, three during the conference week and one the following week.

“The coverage made me feel I was at the conference and I appreciate NAM's effort in sharing the bulletins.” NAM bulletin subscriber

aidsmap news from CROI 2014

Interferon-free BMS combo cures 90% of genotype 1 hepatitis C

An all-oral regimen of daclatasvir, asunaprevir and BMS-791325 – without interferon or ribavirin – led to sustained response in approximately 90% of people with hepatitis C virus

Published
26 March 2014
By
Liz Highleyman
Merck combination suppresses HCV in mono-infected and co-infected patients

An all-oral combination of the hepatitis C virus (HCV) protease inhibitor MK-5172 and NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in people

Published
21 March 2014
By
Liz Highleyman
Early treatment reduces viral reservoirs but does not prevent rebound

Antiretroviral therapy started during the first several days after infection limited dissemination of an HIV-like virus throughout the body and establishment of cellular and tissue reservoirs in monkeys,

Published
21 March 2014
By
Liz Highleyman
Dapivirine vaginal ring safe and effective in tissue study, but maraviroc component doesn't work

Vaginal rings containing the experimental NNRTI dapivirine were well tolerated and blocked HIV infection of cervical tissue samples, but rings containing maraviroc did not produce adequate drug concentrations,

Published
20 March 2014
By
Liz Highleyman
Early antiretroviral therapy may limit gut damage and immune activation

Starting antiretroviral therapy (ART) at the earliest stage of HIV infection can help prevent immune cell dysregulation that contributes to destruction of the gut lining and promotes

Published
20 March 2014
By
Liz Highleyman
Women with circumcised partners less likely to have HIV, no less likely to use condoms

A study from Orange Farm near Johannesburg in South Africa, the area that hosted the first-ever randomised controlled trial of male circumcision for HIV prevention, which concluded in

Published
19 March 2014
By
Gus Cairns
Monitoring may be an option for people living with HIV diagnosed with high-grade pre-cancerous anal lesions

Up to 62% of people living with HIV who have high-grade pre-cancerous cell changes may experience an improvement in their condition over two years without any

Published
18 March 2014
By
Michael Carter
Very different levels of PrEP uptake and adherence in three US cities, demonstration project finds

One of the first studies of open-label pre-exposure prophylaxis (PrEP) for at-risk gay men in three US cities shows that although the proportion of those initially offered or

Published
17 March 2014
By
Gus Cairns
Heart attack link to abacavir persists in D:A:D study

The nucleoside (NRTI) drug abacavir (Ziagen also in Kivexa/Epzicom) continues to be associated with a near-doubling of the risk of a heart attack, according to the latest

Published
14 March 2014
By
Gus Cairns
Daclatasvir plus simeprevir are effective against hepatitis C genotype 1b

An all-oral regimen of daclatasvir plus simeprevir, without interferon or ribavirin, led to sustained response in 85 to 95% of people with hepatitis C genotype 1b, but

Published
13 March 2014
By
Liz Highleyman
← First123...4Next →

Email bulletins

Sign up for our regular email bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.